bristol look well-posit near-term growth follow
celgen acquisit
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim dec
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
adept partnership acquisit bristol-my squibb
built strong portfolio drug robust pipelin strategi
seen recent larg acquisit celgen net
firm excel pipelin strong entrench blood
cancer believ strong overal pipelin help support
wide moat steadi growth potenti
bristol creat strong pipelin brought partner
share develop cost diversifi risk clinic
regulatori failur believ cardiovascular partnership
repres one import partnership manag
blockbust potenti eliqui atrial fibril
bristol discov drug intern like strateg
partner decis move reduc risk lower
develop market cost
within pipelin bristol astut acquisit medarex help
cancer
immunotherapi yield sever major blockbust
compound bristol cancer drug opdivo hold potenti
revolution cancer treatment drive multi-billion-dollar
sale annual base solid efficaci combin potenti
drug strong price power howev competit
merck keytruda like limit bristol opdivo segment
market includ lung cancer
bristol aggress reposit expand
challeng patent loss compani shed diabet
busi medic imag group wound-car divis
nutrit busi effort focu high-margin
specialti drug group recent move acquir celgen move
bristol significantli specialti pharmaceut
segment market celgen drug larg target cancer
tend area strong drug price power
help bristol maintain drug price abil time
govern privat payer push back drug
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
bristol-my squibb discov develop market drug variou
indic cardiovascular oncolog immun disord key
focu bristol immuno-oncolog firm lead drug
develop unlik diversifi peer bristol exit
sever nonpharmaceut busi focu brand specialti drug
tend support strong price power
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
slightli lower bristol fair valu estim
base industri review potenti
litig cost factor discount
cash flow model longer durat regard
celgen acquisit believ deal creat valu
focus oncolog therapeut area overlap
billion annual cost synergi expect
major sg like commerci overlap
overhead make deal posit strateg also
celgen deal diversifi bristol oncolog portfolio
think reduc risk around signific number
late-stag immuno oncolog readout bristol given
bristol
launch
immuno-oncolog drug larger import
indic first-lin nsclc catch
combin treatment import despit
increas challeng larg nsclc market bristol
remain well-posit melanoma renal cancer
although compani face sever patent loss
next year continu strong convict
pipelin expand celgen acquisit led
opdivo potenti significantli alter
treatment paradigm sever major cancer set
project drug reach risk-adjust peak sale close
billion also eliqui cardiovascular diseas
continu grow despit alreadi develop
major blockbust base lead efficaci solid
look whole compani expect averag
annual earn per share growth next five year
help celgen acquisit expect margin
expand high margin celgen drug fold
bristol portfolio high royalti rate paid eliqui
weigh gross margin firm longer
term expect earn fall begin
time period gener pressur key drug revlimid
eliqui emerg
inelast product portfolio
larg base low volatil cash flow
divers
bristol-my uncertainti medium higher
pharma peer group partli high product
bull case probabl
estim rel base case scenario analysi
show moder varianc henc medium uncertainti
rate key factor affect scenario analysi
includ degre success brand drug pipelin
along magnitud competit pressur
current market drug opdivo biggest driver
valuat far rang outcom drug drive
signific portion chang valuat
differ scenario lastli ad potenti
 healthcar polici reform relat drug price
bear case creat addit pressur
base wide line-up patent-protect drug
entrench salesforc economi scale bristol
firm price drug level translat superior
return invest capit compar cost
particularli cancer drug area focu bristol
patent also provid bristol ampl time bring
forward next gener new drug addit
sever bristol current market drug biolog
creat addit hurdl gener firm cost
develop market biosimilar much higher
typic gener small molecul mani
entrench salesforc enabl compani partner
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
administr well increas reluct
part insur compani govern payer
smaller drug compani gain access extern
creat drug augment intern drug-develop
effort addit bristol sheer size gener
strong stabl cash flow requir fund
approxim million need averag bring
new drug market
major patent cliff time period bristol
competit advantag stabil moat trend
stabil result combin fewer upcom
patent loss combin stronger pipelin
pipelin side bristol first-mov advantag
immuno-oncolog set set sever major
blockbust carri high margin
patent protect well next decad project
immuno-oncolog drug off-set patent
loss next three year addit bristol
late-stag pipelin exclus focus unmet medic
need specialty-car indic area debilit
lethal diseas pipelin focu help increas
research develop product fight back
increasingli risk-avers food drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
obristol growth prospect focus new cancer
indic opdivo cardiovascular drug eliqui
hold lead efficaci data within atrial
oth oncolog drug opdivo hold potenti
radic shift treatment paradigm sever
cancer indic result peak sale
billion annual
omor half bristol late-stag pipelin focus
immunolog cancer -- indic
fda aggress approv drug typic
oth acquisit celgen bring gener competit
cancer drug revlimid set major
owe believ larg portion bristol valuat tie
cancer drug opdivo could amplifi
neg impact stock clinic data poor
competitor report superior data opdivo
obristol recent move acquir celgen add
signific debt could becom challeng
repay competit strengthen key drug
price pressur increas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
bristol carri fairli solid financi structur
debt/ebitda project close time howev
recent move acquir celgen expect
debt/ebitda reach time expect
metric fall bristol like pay
debt fairli quickli follow acquisit bristol
cashflow combin celgen cashflow put
firm solid financi foot worst
patent loss begin time period
bristol increas focu brand drug sell
unrel busi line elev exposur
patent loss increas brand drug focu
rais compani depend pipelin
result higher sale volatil observ
diversifi peer addit compani expos
risk face entir pharmaceut group includ
gener threat decreas price power owe
managed-car constraint product liabil case
product-specif standpoint believ compani
largest pipelin risk surround immunotherapi drug
could develop major blockbust fail
market depend clinic data risk
competitor merck roch take market
share immunotherapi rise compani
catch particularli combin therapi lastli
recent move acquir celgen add financi risk due
larg amount debt need financ deal overal
view compani uncertainti medium
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
follow relinquish ceo post lamberto
andreotti giovanni caforio took
ceo view success plan natur progress
andreotti year old transit occur
decad experi pharmaceut industri
doctor caforio bring strong skill set top
posit join bristol caforio
know compani well import
firm fold celgen acquisit
stewardship front rate current manag
standard sever acquisit medarex
excel use capit deal like inhibitex
amylin repres overpay asset firm
largest acquisit celgen look like good use capit
increas fair valu estim follow
deal announc also posit side bristol
aggress cut cost adapt scale
follow patent loss believ help open
capit reinvest busi
cut cost bristol still provid signific fund
toward research develop effort key
creat next gener drug support high
return invest capit
ceo/chairman board/
repres date owner name posit common share held report holder issuer
fidel manag research compani
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
bristol post steadi third quarter led eliqui
celgen deal set close year-end oct
slightli ahead expect dont expect
major chang fair valu estim base minor
out-performance despit stock recent runup still
view bristol under-valued market fulli
appreci firm pipelin includ celgen
pipelin
larg focus oncolog
immunolog area typic hold strong price power
strong combin pipelin solid entrench
immuno-oncolog reinforc wide moat rate
quarter total sale increas oper led
cardiovascular drug eliqui offset matur
product declin deceler growth immuno-
oncolog drug opdivo expect trend continu
eliqui look well posit continu take
share older drug warfarin also opdivo like fall
number patient avail second-
line non-small-cel lung cancer market shrink
patient move first-lin segment merck
well posit expect bristol
combin opdivo plu yervoy gain approv first-
line nsclc base posit data checkmat
unless detail data show
significantli better data keytruda continu
believ bristol penetr
metastat nsclc market outsid nsclc expect
bristol immuno-oncolog platform perform well
melanoma renal cancer
bristol track close celgen acquisit year-
end believ deal strengthen firm pipelin
beyond immunolog drug addit
rel weak increas import celgen
inreb fedratinib myelofibrosi ozanimod multipl
sclerosi blood cancer drug liso-cel
complet review bristol celgen pipelin
secur
innov counter price gener
headwind acceler
bristol lung cancer data favor checkmat
merck lead look secur sep
bristol-my report posit final data part one
chemotherapi first-lin non-smal cell lung cancer
nsclc dont expect signific chang
fair valu base data continu view bristol
under-valued acquisit celgen pipelin
fulli appreci market also continu
expect bristol focu oncolog drug drive strong
price power reinforc compani wide moat
cross-trial comparison drawback efficaci
bristol combin opdivo plu yervoy checkmat
doesnt look well posit merck keytruda-
plu chemotherapi howev patient
express approxim three quarter
patient adamantli use chemotherapi especi
due neutropenia anemia side effect issu bristol
combin offer best altern bristol
data low expressor less express
look competit trial design may limit
inclus sub-seg data label also data
squamou patient also
look competit
nevertheless merck control first-mov
advantag lead efficaci data believ keytruda
gain close first-lin metastat nsclc
market follow roch tecentriq bristol
opdivo includ yervoy one last remain
studi patient popul bristol checkmat
read first-half studi
includ chemotherapi prime help patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
aggress form diseas addit
control crossov import studi
believ part reason merck keytruda shown
rel strong overal surviv data relat limit
amount crossov chemotherapi arm
beyond first-lin nsclc expect next wave
import immuno-oncolog data address earli stage
cancer adjuv neoadjuv earli stage lung
cancer alon project close billion annual sale
probabl weight estim
probabl success earli treatment set
complet overview adjuvant/neoadjuv lung
market immuno oncolog drug pleas see report
titl immuno-oncolog drug adjuv lung
frontier strengthen moat
bristol sale otezla fair price
bristol-my squibb divest psoriasi drug otezla
billion repres price close
fair valu estim drug expect
major impact fair valu estim moat
firm deal appeas anti-trust
concern regul pend acquisit
celgen bristol follow announc divest
bristol guid close celgen deal late
slightli ahead previou guidanc think
updat guidanc reason
surpris potenti ownership
bristol pipelin psoriasi drug bm celgen
otezla caus anti-trust concern feder trade
commiss bristol face fire sale price otezla
continu view stronger two
psoriasi drug expect drug reach market
asset combin sever pipelin
perspect otezla add support
near-term growth project three-year compound
growth rate drug along exclus
least longer market also
strong presenc understand psoriasi market
develop commerci enbrel
mean rel smooth transit market otezla
longer term expect take share
otezla base stronger efficaci seen earli stage
studi drug offer conveni oral
administr addit expect
take share biolog psoriasi drug base easier
oral dose versu inject superior efficaci
complet review outlook psoriasi
remain secur innov counter price gener
headwind acceler
bristol post mix checkmat data
backdrop strong result jul
tandem second-quart result exceed
consensu expect bristol-my squibb
report mix trial data import checkmat
studi opdivo yervoy first-lin non-smal cell lung
cancer aggreg expect major chang
fair valu estim base updat
continu view firm under-valued market
underappreci potenti cash flow driven drug
treat unmet medic need price power high
strong posit also reinforc wide moat rate
firm
checkmat studi report unusu result
opdivo plu chemotherapi show statist
advantag versu chemotherapi alon opdivo
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
plu yervoy arm studi show signific benefit
expect combin therapi work
success outcom opdivo plu yervoy could allow
differenti data show
success combin import
given bristol late first-lin nsclc market
follow merck roch opdivo plu yervoy
treatment work patient express
group patient competit drug less
success exact amount benefit bristol drug
import determin shift market share
expect detail data releas medic
confer later year overal continu expect
bristol gain close nsclc market
quarter total sale grew oper buoy
growth opdivo cardiovascular drug eliqui
expect continu growth eliqui base
best-in-class stand expect declin due
increas competit pressur lung cancer howev
expect opdivo growth reacceler base
checkmat data addit new indic
outsid lung cancer
celgen acquisit remain track close late
earli complet review bristol
report moat remain secur innov counter
price gener headwind acceler
senat financ committe chairman chuck grassley
democrat rank member ron wyden post
prescript drug price reduct act tuesday
although final bill need proceed
mark-up thursday get major vote full
committe could see chang proce
senat floor vote like mean bipartisan
agreement reach prior post share price
drug firm larg unmov news
think progress senat make less like
sever hh rule intern price benchmark
medicar part implement also mean
increasingli like legisl could hold price
increas extent make fair valu
estim chang news continu watch
updat senat follow thursday mark-up
hous like propos legisl
septemb caution possibl bipartisan
bill could pass senat fail hous
progress democrat will compromis
certain issu exampl medicar part direct
negoti includ pdpra regardless
expect overhang drug stock next sever
month drug price overhaul remain key topic
washington result continu see industri
under-valued despit strong product increasingli
overal propos pdpra similar
discuss recent analysi rebat rule dead
signific benefit pdpra compar
rebat rule cost congression budget offic
cbo estim rebat rule would result
billion extra feder spend year
assum current rebat withheld contrast
cbo estim pdpra would save taxpay
billion year billion save
medicaid mostli increas maximum rebat
billion save medicar within medicar
save larg split part redesign
billion inflation-reb polici billion
would forc drugmak pay addit rebat drug
medicar part part price increas
exceed inflat cpi-u roughli annual
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
addit two medicar polici would help
beneficiari lower pocket cost premium
total billion year cbo also assum
inflation-reb provis would reduc drug cost
patient privat insur part redesign
would substanti effect patient
think unclear impact pdpra could
patient cover privat insur drugmak could
continu rais price privat market simpli pay
addit rebat necessari medicar
of-pocket cost previous patient paid drug cost
catastroph phase limit
patient enter catastroph coverag phase drug
firm would hook drug cost
elimin current coverag gap discount drug firm
pay cost coverag gap introduc
new respons higher spend level
discuss recent research see firm like gilead
hepat hiv treatment bristol/celgen cancer
therapi revlimid potenti expos peer
among highest-profil provis pdpra
propos cap medicar part part price increas
inflationari level begin excess price
increas would need return medicar form
rebat part expect larg
impact even firm high exposur channel
biggest drug program take
larg price increas reimburs system alreadi
discourag instead reli high launch price
profit exampl among top drug medicar
part spend accord medicar drug
spend dashboard one saw averag annual price
increas
neulasta newer blockbust bristol opdivo
merck keytruda top annual price
increas part expect could
drug higher list price increas could
impact dashboard spend data indic averag
annual price increas top drug around
rebat rule dead suppli chain benefit drug firm
pressur estim drug firm exposur
anoth key part pdpra drug manufactur
perspect medicar part redesign could
implement would hit firm
expens drug hardest chang would cap out-
first report juli axio trump administr
plan final propos rule alter flow
drug rebat purchas medicar part plan
rule would chang busi model
pharmaci benefit manag requir negoti
discount pass directli beneficiari
point sale rather use mechan lower
cost insur plan overal led ralli
pbms/insur distributor drug stock sank
investor wonder presid donald trump focu
turn next take rebat reform tabl put
pressur congress particularli bipartisan senat
financ committe team chuck grassley ron wyden
reveal drug-pric packag month stand
chanc pass chamber potenti reform
like reduc cost medicar patient also look
modest payer drug firm
think remain propos review
budget offic -- medicar part intern price
index -- unlik implement even final
congress power block rule judici review
could find massiv demonstr overextens
author center medicar medicaid
innov cmmi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
altern expect senat drug price packag
could includ part reform also includ cap
out-of-pocket spend medicar part anticip
propos would see widespread support
policymak result higher likelihood
success think chang would manag
drug firm effect achiev bipartisan
polici goal lower healthcar cost american
addit detail analysi effect
rebat rule elimin pleas see report rebat
bristol opdivo liver cancer setback forc sale
otezla mild neg jun
tandem announc fail opdivo studi
liver cancer bristol-my squibb also announc
forc divest psoriasi drug otezla appeas
regul regard celgen acquisit see
announc mild neg expect
major chang fair valu estim continu
view bristol well entrench immuno-oncolog
market opdivo acquisit celgen still
look solid despit otezla divest view
event signific impact bristol wide
bristol announc fail studi
opdivo liver cancer hurt potenti drug
estim less opdivo sale would
come first-lin liver cancer liver studi
on-going support opdivo use liver
cancer market addit think read-
studi on-going opdivo studi
cancer indic
also feder trade commiss forc
divest otezla clear bristol acquisit
celgen surpris ftc forc
divest bristol psoriasi drug
inhibitor yet approv differ mechan
action nevertheless expect sever interest
compani bid divest think
unlik bristol take fire-sal price howev
slightli concern whether bristol still
abl achiev billion annual cost synergi
associ celgen acquisit view
psoriasi portfolio key area synergi
compani bristol expect acquisit close
late earli slight delay origin
guidanc third quarter view
concern especi sinc compani need time
complet review bristol celgen pipelin
secur
innov counter price gener
headwind acceler
immuno-oncolog drug adjuv lung
frontier strengthen moat jun
innov immuno-oncolog drug support
econom moat merck roch bristol-my squibb
astrazeneca expect expans
adjuvant/neoadjuv set strengthen moat
project lung adjuvant/neoadjuv market expand
potenti close billion annual sale
probability-weight ad almost billion
project late-stag metastat set estim
probabl success early-treat set
base earli clinic data strength drug
late-stag set view merck roch best
posit adjuv set due first-mov
advantag upcom clinic data
bristol astra earlier data
neoadjuv set skeptic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chemotherapi show strong enough efficaci
competit overal includ early- late-stag
set believ potenti immuno-oncolog drug
sale underappreci merck roch
see compani under-valued
complet report potenti immuno-
oncolog drug adjuv set focu
lung cancer indic pleas see report immuno-
oncolog drug adjuv lung frontier
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
